As part of our coverage of the AACR Annual Meeting, we discuss combination therapies and new research in the treatment of lung cancer.
Advanced melanoma patients treated with the anti–PD-1 inhibitor MK-3475 with tumors that expressed PD-L1 had higher survival rates and more robust immune responses compared with patients with tumors that did not express PD-L1.
Loss of the tumor suppressor PTEN was found to be a frequent mechanism of resistance to treatment with the PI3K-alpha inhibitor BYL719 in women with breast cancer.
A high body mass index prior to a colorectal cancer diagnosis is linked to a higher risk of death, even when the patient’s tumor type is generally associated with a better prognosis.
Researchers have identified a potential biomarker that may confer inherent resistance to enzalutamide for patients with castration-resistant prostate cancer.
Two early trials studying CDK inhibitors in metastatic breast cancer have shown impressive activity in HR-positive disease, according to data presented at the AACR annual meeting.
In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.
New trial results show that a novel, oral metabolic inhibitor has demonstrated early activity in relapsed or refractory acute myeloid leukemia (AML), according to data presented at the annual meeting of the American Association of Cancer Research.